Geron Corp (GERN):企業の財務・戦略的SWOT分析

◆英語タイトル:Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH42160FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Geron Corp (GERN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Geron Corp (Geron) is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of imetelstat, a first-in-class telomerase inhibitor in hematologic myeloid malignancies. The company’s clinical studies include IMerge, a Phase 2 trial in lower risk myelodysplastic syndromes; and IMbark, a Phase 2 clinical trial in intermediate or high-risk myelofibrosis. Imetelstat received Fast Track designation from the US FDA to treat patients with transfusion-dependent anemia due to lower or intermediate risk myelodysplastic syndromes (MDS) and patients with intermediate or high-risk myelofibrosis (MF). The company utilizes core expertise in telomerase and telomere biology and its proprietary nucleic acid chemistry for the development of imetelstat. Geron is headquartered in Menlo Park, California, the US.

Geron Corp Key Recent Developments

Mar 11,2021: Geron Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 01,2021: Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Nov 05,2020: Geron reports third quarter 2020 financial results and current events
Oct 29,2020: Geron to Announce Third Quarter Financial Results on November 5, 2020
Aug 06,2020: Geron reports second quarter 2020 financial results and current events

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Geron Corp – Key Facts
Geron Corp – Key Employees
Geron Corp – Key Employee Biographies
Geron Corp – Major Products and Services
Geron Corp – History
Geron Corp – Company Statement
Geron Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Geron Corp – Business Description
R&D Overview
Geron Corp – SWOT Analysis
SWOT Analysis – Overview
Geron Corp – Strengths
Geron Corp – Weaknesses
Geron Corp – Opportunities
Geron Corp – Threats
Geron Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Geron Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Geron Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2021: Geron Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 01, 2021: Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Nov 05, 2020: Geron reports third quarter 2020 financial results and current events
Oct 29, 2020: Geron to Announce Third Quarter Financial Results on November 5, 2020
Aug 06, 2020: Geron reports second quarter 2020 financial results and current events
May 28, 2020: Geron reports first quarter 2020 financial results
Mar 12, 2020: Geron reports fourth quarter and full year 2019 financial results and 2020 milestones
Feb 14, 2020: GERON: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jan 13, 2020: Geron announces 2019 accomplishments and key development priorities for 2020
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Geron Corp, Key Facts
Geron Corp, Key Employees
Geron Corp, Key Employee Biographies
Geron Corp, Major Products and Services
Geron Corp, History
Geron Corp, Other Locations
Geron Corp, Key Competitors
Geron Corp, Ratios based on current share price
Geron Corp, Annual Ratios
Geron Corp, Annual Ratios (Cont...1)
Geron Corp, Interim Ratios
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Geron Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Geron Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Geron Corp (GERN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kansai Paint Co Ltd (4613):企業の財務・戦略的SWOT分析
    Kansai Paint Co Ltd (4613) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Hadera Paper Ltd.:企業の戦略・SWOT・財務情報
    Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Immune Pharmaceuticals Inc (IMNP):企業の財務・戦略的SWOT分析
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • Acasti Pharma Inc (APO):企業の財務・戦略的SWOT分析
    Summary Acasti Pharma Inc (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, development, and commercialization of krill oil-based forms of omega-3 fatty acids. The company develops phospholipid therapies for abnormalities in bl …
  • Pentax Europe GmbH-医療機器分野:企業M&A・提携分析
    Summary Pentax Europe GmbH (Pentax Medical), a subsidiary of Hoya Corp is a medical device company that provides clinical endo-imaging solutions. The company offers products in the therapeutic areas of gastroenterology, endoscopic ultrasound, ENT and speech, pulmonology, and urology. Its products in …
  • Alliqua BioMedical Inc (ALQA)-製薬・医療分野:企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Abu Dhabi National Oil Co-石油・ガス分野:企業M&A・提携分析
    Summary Abu Dhabi National Oil Company (ADNOC) is a vertically integrated national oil and gas group. The group is active in exploration and production, support services, oil refining and gas processing, chemicals and petrochemicals, maritime transportation and refined products and distribution. ADN …
  • Instituto Costarricense de Electricidad-エネルギー分野:企業M&A・提携分析
    Summary Instituto Costarricense de Electricidad (ICE) is an autonomous institution of the Government of Costa Rica that provides electricity and telecommunications services. The company generates, transmits and distributes electricity; and constructs, operates, and maintains power plants. It uses cl …
  • Teradyne Inc (TER):企業の財務・戦略的SWOT分析
    Teradyne Inc (TER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • WKN AG:電力:M&Aディール及び事業提携情報
    Summary WKN AG (WKN), formerly WKN WindKraft Nord AG, a subsidiary of PNE Wind AG, is a renewable energy service provider that develops wind farms and various photovoltaic projects. The company offer services portfolio includes project planning, development, financing, realisation, and repowering. I …
  • Invion Ltd (IVX):製薬・医療:M&Aディール及び事業提携情報
    Summary Invion Ltd (Invion) is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company's pipeline products include INV102 nadolol, a beta adrenergic biased ligand …
  • Inabata & Co Ltd (8098):企業の財務・戦略的SWOT分析
    Inabata & Co Ltd (8098) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Medovex Corp (MDVX):医療機器:M&Aディール及び事業提携情報
    Summary Medovex Corp (Medovex) is a medical device company. The company operates in designing and marketing medical devices for commercial use. It offers DenerveX device, a disposable single-use kit for the treatment of various medical applications including pain relief from chronic back pain caused …
  • United Utilities Group PLC:企業の戦略・SWOT・財務分析
    United Utilities Group PLC - Strategy, SWOT and Corporate Finance Report Summary United Utilities Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Nurix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Nurix Inc (Nurix) formerly Kura Therapeutics Inc, is a drug development company that discovers and develops drugs which work by modulating the protein regulation machinery of the cell. The company developed a drug discovery platform based on understanding of the ubiquitin proteasome system ( …
  • Urban One Inc (UONEK):企業の財務・戦略的SWOT分析
    Urban One Inc (UONEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • AptarGroup Inc:企業の戦略・SWOT・財務分析
    AptarGroup Inc - Strategy, SWOT and Corporate Finance Report Summary AptarGroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Sage Group plc (SGE):企業の財務・戦略的SWOT分析
    The Sage Group plc (SGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Gr. Sarantis S.A. (SAR):企業の財務・戦略的SWOT分析
    Gr. Sarantis S.A. (SAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Global Investment House KPSC:企業の戦略的SWOT分析
    Global Investment House KPSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆